📣 AstraZeneca Bets on AI for Cancer Treatments
posted 4 Dec 2023

Pharmaceutical giant AstraZeneca signed a $247 million deal with biotech firm Absci, specializing in AI-driven drug development. This partnership aims to innovate cancer treatment methods.
Pharmaceutical giant AstraZeneca signed a $247 million deal with biotech
firm Absci, specializing in AI-driven drug development. This
partnership aims to innovate cancer treatment methods.
"We're
proud to work closely with AstraZeneca to leverage our AI to bring
novel treatments to oncology patients," Absci CEO Sean McClain said.